Drug Therapy and Personalized Health Care: Pharmacogenomics in Perspective

[1] Mullard A.(2008)The inside story Nature. 453 578-580

[2] Sadée W.(2005)Pharmacogenetics/genomics and personalized medicine Hum. Mol. Genet. 14 R207-R214

[3] Dai Z.(2004)Moving towards individualized medicine with pharmacogenomics Nature. 429 464-4688

[4] Evans W. E.(2008)ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use Genet. Med. 10 139-150

[5] Relling M. V.(2001)The potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review J. Amer. Med. Assn. 286 2270-2279

[6] Flockhart D. A.(1998)Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies JAMA. 279 1200-12055

[7] O'Kane D.(2005)Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects Circulation. 111 278-287

[8] Williams M. S.(2008)microRNAs modulate the chemosensitivity of tumor cells Molec.Cancer Therap. 7 1-9

[9] Watson M. S.(2008)Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. Pharmacogen. Genom 18 781-791

[10] Gage B.(2005)Polymorphisms affecting gene regulation and mRNA processing: Broad implications for pharmacogenetics Pharmacol. Ther. 106 19-38

[1] Mullard A.(2008)The inside story Nature. 453 578-580

[2] Sadée W.(2005)Pharmacogenetics/genomics and personalized medicine Hum. Mol. Genet. 14 R207-R214

[3] Dai Z.(2004)Moving towards individualized medicine with pharmacogenomics Nature. 429 464-4688

[4] Evans W. E.(2008)ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use Genet. Med. 10 139-150

[5] Relling M. V.(2001)The potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review J. Amer. Med. Assn. 286 2270-2279

[6] Flockhart D. A.(1998)Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies JAMA. 279 1200-12055

[7] O'Kane D.(2005)Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects Circulation. 111 278-287

[8] Williams M. S.(2008)microRNAs modulate the chemosensitivity of tumor cells Molec.Cancer Therap. 7 1-9

[9] Watson M. S.(2008)Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. Pharmacogen. Genom 18 781-791

[10] Gage B.(2005)Polymorphisms affecting gene regulation and mRNA processing: Broad implications for pharmacogenetics Pharmacol. Ther. 106 19-38